Market Overview (August 2026)

The Shanghai and Shenzhen exchanges recorded a combined trading volume of 1.81 trillion CNY on 26 August 2026, reflecting a decline of 231 billion CNY from the previous day. Major indices ended the session with modest gains:

  • Shanghai Composite – up 0.59 % to 3 912.52 points
  • Shenzhen Component – up 0.69 % to 13 841.33 points
  • ChiNext – up 0.51 % to 3 414.88 points

Sector‑level activity was dominated by strong performances in large‑financial, precious‑metal, and green‑energy segments, while commodity‑related stocks experienced a broader decline.

Shenqi Pharmaceutical (600613)

Trading Activity

  • 25 August 2026 – The stock achieved a daily turnover of 1.502 billion CNY, the highest since 21 November 2022. The closing price increased by 3.43 % and the turnover rate rose to 32 %.
  • 26 August 2026 – Shenqi Pharmaceutical was listed among 48 A‑share stocks with a turnover rate exceeding 20 %. The trading data for the day reported a turnover of 15.02 billion CNY and a price rise of 3.43 %.
  • 24 August 2026 – The company issued a formal notice of abnormal trading activity and risk warning. The notice referenced an external document detailing the event.

Stock Performance Context

On 24 August, the overall market was characterised by a slight decline in the ChiNext index and a moderate rise in the Shanghai Composite. Within this backdrop, Shenqi Pharmaceutical’s high turnover and price appreciation stood out as notable anomalies. The company’s trading patterns were highlighted in a midday analysis that identified 41 gainers and 9 laggers, with Shenqi listed among the six‑day consecutive winners.

Regulatory and Company Information

Shenqi Pharmaceutical is registered as Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., established on 22 July 1992, with a registered capital of 534 071,628 CNY. The company’s latest market data (as of 24 August 2026) shows a closing price of 10.27 CNY, a 52‑week high of 10.28 CNY, a 52‑week low of 4.33 CNY, and a market capitalisation of 5 426 167 296 CNY. The price‑earnings ratio stands at 162.26.

Summary

Shenqi Pharmaceutical displayed significant trading activity and price movement during the week of 24–26 August 2026, contrasting with broader market volatility. The company’s high turnover, coupled with regulatory disclosure of abnormal trading, suggests heightened investor interest and warrants close monitoring of subsequent market developments.